|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
| We’re going down soon, to move to a new Data Center today. We’ll be up ASAP. Sorry. |
As Of Filer Filing For·On·As Docs:Size 11/06/20 Obalon Therapeutics Inc. 10-Q 9/30/20 60:5.2M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 388K
2: EX-10.1 Material Contract HTML 354K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 24K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
12: R1 Document and Entity Information HTML 48K
13: R2 Condensed Consolidated Balance Sheets HTML 97K
14: R3 Condensed Consolidated Balance Sheets HTML 26K
(Parenthetical)
15: R4 Condensed Consolidated Statements of Operations HTML 66K
and Comprehensive Loss
16: R5 Condensed Consolidated Statements of Stockholders' HTML 107K
Equity
17: R6 Condensed Consolidated Statements of Cash Flows HTML 109K
18: R7 Organization and Basis of Presentation HTML 30K
19: R8 Summary of Significant Accounting Policies HTML 39K
20: R9 Fair Value Measurements HTML 83K
21: R10 Net Loss per Share HTML 45K
22: R11 Balance Sheet Details HTML 69K
23: R12 Loan HTML 24K
24: R13 Stock-Based Compensation HTML 89K
25: R14 Stockholders' Equity HTML 37K
26: R15 Income Taxes HTML 22K
27: R16 Commitments and Contingencies HTML 45K
28: R17 Variable Interest Entity HTML 22K
29: R18 Summary of Significant Accounting Policies HTML 59K
(Policies)
30: R19 Fair Value Measurements (Tables) HTML 83K
31: R20 Net Loss per Share (Tables) HTML 47K
32: R21 Balance Sheet Details (Tables) HTML 72K
33: R22 Stock-Based Compensation (Tables) HTML 93K
34: R23 Stockholders' Equity (Tables) HTML 23K
35: R24 Commitments and Contingencies (Tables) HTML 32K
36: R25 Organization and Basis of Presentation - HTML 38K
Additional Information (Detail)
37: R26 Summary of Significant Accounting Policies - HTML 23K
Narrative (Details)
38: R27 Fair Value Measurements - Schedule of Assets and HTML 49K
Liabilities Measured at Fair Value on Recurring
Basis (Details)
39: R28 Fair Value Measurements - Schedule of Fair Value HTML 32K
Assumptions (Details)
40: R29 Fair Value Measurements - Schedule of Liabilities HTML 26K
Measured at Fair Value (Details)
41: R30 Net Loss per Share - Schedule of Computation of HTML 32K
Basic and Diluted Net Loss Per Share of Common
Stock (Details)
42: R31 Net Loss per Share - Schedule of Anti-Dilutive HTML 24K
Common Stock Equivalents Excluded from the
Calculation of Diluted Net Loss Per Share
(Details)
43: R32 Balance Sheet Details - Schedule of Inventory HTML 27K
(Details)
44: R33 Balance Sheet Details - Narrative (Details) HTML 28K
45: R34 Balance Sheet Details - Schedule of Other Current HTML 28K
Assets (Details)
46: R35 Balance Sheet Details - Schedule of Property and HTML 45K
Equipment, Net (Details)
47: R36 Balance Sheet Details - Schedule of Other Current HTML 35K
Liabilities (Details)
48: R37 Loan - Additional Information (Details) HTML 24K
49: R38 Stock-Based Compensation - Additional Information HTML 36K
(Details)
50: R39 Stock-Based Compensation - Summary of Stock-Based HTML 28K
Compensation (Details)
51: R40 Stock-Based Compensation - Summary of Stock Option HTML 70K
Transactions (Details)
52: R41 Stock-Based Compensation - Summary of Restricted HTML 58K
Stock Awards (Details)
53: R42 Stockholders' Equity - Additional Information HTML 70K
(Details)
54: R43 Stockholders' Equity - Schedule of Common Stock HTML 28K
Reserved for Future Issuance (Details)
55: R44 Commitments and Contingencies - Additional HTML 51K
Information (Details)
56: R45 Commitments and Contingencies - Schedule of Future HTML 50K
Noncancelable Minimum Payment Obligations Under
Operating Lease (Details)
57: R46 Variable Interest Entity (Details) HTML 23K
59: XML IDEA XML File -- Filing Summary XML 103K
58: EXCEL IDEA Workbook of Financial Reports XLSX 71K
6: EX-101.INS XBRL Instance -- obln-20200930 XML 1.22M
8: EX-101.CAL XBRL Calculations -- obln-20200930_cal XML 174K
9: EX-101.DEF XBRL Definitions -- obln-20200930_def XML 327K
10: EX-101.LAB XBRL Labels -- obln-20200930_lab XML 1.15M
11: EX-101.PRE XBRL Presentations -- obln-20200930_pre XML 647K
7: EX-101.SCH XBRL Schema -- obln-20200930 XSD 112K
60: ZIP XBRL Zipped Folder -- 0001427570-20-000062-xbrl Zip 149K
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/6/20 | 8-K | ||
| For Period end: | 9/30/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/09/21 ReShape Lifesciences Inc. S-4/A 89:13M Toppan Merrill/FA 3/30/21 ReShape Lifesciences Inc. S-4 25:18M Toppan Merrill/FA 3/12/21 ReShape Lifesciences Inc. 10-K 12/31/20 83:8.4M Toppan Merrill Bridge/FA 2/03/21 ReShape Lifesciences Inc. S-8 2/03/21 3:211K Toppan Merrill Bridge/FA |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/14/20 ReShape Lifesciences Inc. 8-K:1,3,9 8/14/20 3:203K 7/24/19 ReShape Lifesciences Inc. 8-K:3,5,8,9 7/23/19 3:71K 6/14/18 ReShape Lifesciences Inc. 8-K:5,9 6/14/18 2:53K 9/26/16 ReShape Lifesciences Inc. S-1/A 17:4M Donnelley … Solutions/FA |